LB-P2D / LISCure Biosci - LARVOL DELTA

LISCure Biosciences Announces Research Collaboration with The Scripps Research Institute for Immuno-Oncology (PRNewswire) - "LISCure Biosciences...announced that it had reached an agreement with The Scripps Research Institute ('Scripps Research') to collaboratively research on bacteria-mediated immuno-oncology candidates against multiple cancer types....With this collaboration, LISCure and Scripps Research scientists will jointly discover novel mechanisms of LB-P2D involved in its multifaceted antitumor immune signals and research on the combination with immune checkpoint inhibitors....LISCure plans to enter the first-in-human study in the US for LB-P2D in 2H 2022."

Licensing / partnership • New trial • Oncology • Solid Tumor